Quotes 5-day view Delayed Japan Exchange
06/29/2022
06/30/2022
07/01/2022
07/04/2022
07/05/2022
Date
6840(c)
6855(c)
6734(c)
6837(c)
6985
Last
1 147 900
1 307 100
1 235 500
1 151 300
1 059 800
Volume
-0.26%
+0.22%
-1.77%
+1.53%
+2.16%
Change
Estimated financial data (e) JPY USD
Sales 2022
311 B
2 289 M
2 289 M
Net income 2022
106 B
784 M
784 M
Net cash position 2022
356 B
2 625 M
2 625 M
P/E ratio 2022
19,1x
Yield 2022
1,63%
Sales 2023
393 B
2 893 M
2 893 M
Net income 2023
140 B
1 032 M
1 032 M
Net cash position 2023
379 B
2 789 M
2 789 M
P/E ratio 2023
14,6x
Yield 2023
1,77%
Capitalization
2 061 B
15 190 M
15 190 M
EV / Sales 2022
5,49x
EV / Sales 2023
4,29x
Nbr of Employees
5 485
Free-Float
90,1%
Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products:
- prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.;
- OTC products: analgesic products, vitamins and tonics, etc.;
- diagnosis products: primarily for detection and...
Ratings of Shionogi & Co., Ltd.
All news about SHIONOGI & CO., LTD.
News in other languages on SHIONOGI & CO., LTD.
Analyst Recommendations on SHIONOGI & CO., LTD.
GSK to get $1.25 billion to settle HIV drug patent row with Gilead
Chart SHIONOGI & CO., LTD.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SHIONOGI & CO., LTD.
Short Term Mid-Term Long Term Trends Neutral Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
6 837,00 JPY
Average target price
7 944,62 JPY
Spread / Average Target
16,2%
Please enable JavaScript in your browser's settings to use dynamic charts.